Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
$9.69
-0.7%
$10.38
$6.37
$15.37
$1.29B1.061.12 million shs1.74 million shs
Omnicell, Inc. stock logo
OMCL
Omnicell
$29.96
-1.1%
$27.91
$25.69
$77.14
$1.38B0.77537,376 shs357,297 shs
Phreesia, Inc. stock logo
PHR
Phreesia
$21.96
-2.8%
$23.16
$12.05
$34.98
$1.24B0.95505,888 shs266,212 shs
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$46.26
-1.2%
$42.59
$3.69
$53.82
$1.56B-1.51360,240 shs427,837 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
-0.72%-3.68%-6.83%+36.29%-14.25%
Omnicell, Inc. stock logo
OMCL
Omnicell
-1.12%+10.27%+7.38%+2.96%-54.22%
Phreesia, Inc. stock logo
PHR
Phreesia
-2.83%+4.52%-4.06%-18.71%-21.60%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-1.15%-2.69%+14.76%-2.57%+970.83%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
3.9063 of 5 stars
3.23.00.00.01.03.33.8
Omnicell, Inc. stock logo
OMCL
Omnicell
2.2533 of 5 stars
3.21.00.00.02.51.71.9
Phreesia, Inc. stock logo
PHR
Phreesia
4.3656 of 5 stars
4.42.00.04.21.32.50.6
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3.5939 of 5 stars
2.50.00.04.62.64.20.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
2.33
Hold$12.2626.49% Upside
Omnicell, Inc. stock logo
OMCL
Omnicell
2.33
Hold$42.2040.85% Upside
Phreesia, Inc. stock logo
PHR
Phreesia
2.86
Moderate Buy$31.6243.97% Upside
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3.00
Buy$55.6020.19% Upside

Current Analyst Ratings

Latest OMCL, PHR, AHCO, and SLNO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/30/2024
Omnicell, Inc. stock logo
OMCL
Omnicell
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$38.00
3/22/2024
Phreesia, Inc. stock logo
PHR
Phreesia
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$28.00
3/21/2024
Phreesia, Inc. stock logo
PHR
Phreesia
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$23.00
3/21/2024
Phreesia, Inc. stock logo
PHR
Phreesia
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$28.00 ➝ $30.00
3/18/2024
Phreesia, Inc. stock logo
PHR
Phreesia
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$30.00 ➝ $31.00
3/15/2024
Phreesia, Inc. stock logo
PHR
Phreesia
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$36.00 ➝ $37.00
3/15/2024
Phreesia, Inc. stock logo
PHR
Phreesia
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$32.00
3/15/2024
Phreesia, Inc. stock logo
PHR
Phreesia
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$28.00
3/15/2024
Phreesia, Inc. stock logo
PHR
Phreesia
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$25.00 ➝ $30.00
3/15/2024
Phreesia, Inc. stock logo
PHR
Phreesia
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$17.00 ➝ $23.00
3/15/2024
Phreesia, Inc. stock logo
PHR
Phreesia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00
(Data available from 5/9/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
$3.20B0.40$9.89 per share0.98$11.06 per share0.88
Omnicell, Inc. stock logo
OMCL
Omnicell
$1.10B1.25$3.13 per share9.58$26.15 per share1.15
Phreesia, Inc. stock logo
PHR
Phreesia
$356.30M3.48N/AN/A$4.52 per share4.86
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/A$5.16 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
-$678.90M-$5.31N/A8.650.67-21.21%8.84%3.39%8/13/2024 (Estimated)
Omnicell, Inc. stock logo
OMCL
Omnicell
-$20.37M-$0.46N/A83.22237.43-1.91%2.41%1.28%8/6/2024 (Estimated)
Phreesia, Inc. stock logo
PHR
Phreesia
-$136.88M-$2.52N/AN/AN/A-38.42%-53.33%-38.04%5/30/2024 (Confirmed)
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$38.99M-$2.97N/AN/AN/AN/A-79.65%-52.92%5/14/2024 (Estimated)

Latest OMCL, PHR, AHCO, and SLNO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/30/2024N/A
Phreesia, Inc. stock logo
PHR
Phreesia
-$0.51N/A+$0.51N/AN/AN/A  
3/14/2024Q4 2024
Phreesia, Inc. stock logo
PHR
Phreesia
-$0.58-$0.56+$0.02-$0.56$93.52 million$95.00 million    
3/6/2024Q4 2023
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$0.31-$0.33-$0.02-$0.33N/AN/A
2/27/2024Q4 2023
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
$0.20$0.64+$0.44$3.19$825.94 million$858.23 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
N/AN/AN/AN/AN/A
Omnicell, Inc. stock logo
OMCL
Omnicell
N/AN/AN/AN/AN/A
Phreesia, Inc. stock logo
PHR
Phreesia
N/AN/AN/AN/AN/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
1.44
1.21
1.00
Omnicell, Inc. stock logo
OMCL
Omnicell
0.48
2.38
2.13
Phreesia, Inc. stock logo
PHR
Phreesia
0.02
1.78
1.78
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/A
14.89
14.89

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
82.67%
Omnicell, Inc. stock logo
OMCL
Omnicell
97.70%
Phreesia, Inc. stock logo
PHR
Phreesia
92.10%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
97.42%

Insider Ownership

CompanyInsider Ownership
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
13.60%
Omnicell, Inc. stock logo
OMCL
Omnicell
2.64%
Phreesia, Inc. stock logo
PHR
Phreesia
5.80%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
28.80%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
10,700132.91 million114.83 millionOptionable
Omnicell, Inc. stock logo
OMCL
Omnicell
3,65045.92 million44.71 millionOptionable
Phreesia, Inc. stock logo
PHR
Phreesia
1,43856.39 million53.12 millionOptionable
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3333.41 million23.79 millionOptionable

OMCL, PHR, AHCO, and SLNO Headlines

SourceHeadline
While institutions invested in Soleno Therapeutics, Inc. (NASDAQ:SLNO) benefited from last weeks 4.8% gain, private equity firms stood to gain the mostWhile institutions invested in Soleno Therapeutics, Inc. (NASDAQ:SLNO) benefited from last week's 4.8% gain, private equity firms stood to gain the most
finance.yahoo.com - May 8 at 11:07 AM
Soleno Therapeutics (NASDAQ:SLNO) Shares Gap Down to $49.23Soleno Therapeutics (NASDAQ:SLNO) Shares Gap Down to $49.23
americanbankingnews.com - May 5 at 3:38 AM
Vivo Opportunity, Llc Sells 750,000 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) StockVivo Opportunity, Llc Sells 750,000 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) Stock
americanbankingnews.com - May 3 at 4:04 AM
Soleno Therapeutics Prices Public Offering Of 3 Mln Shares At $46/shr; Stock Down In After-hoursSoleno Therapeutics Prices Public Offering Of 3 Mln Shares At $46/shr; Stock Down In After-hours
nasdaq.com - May 3 at 1:48 AM
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common StockSoleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock
globenewswire.com - May 2 at 10:32 PM
Soleno Therapeutics Announces Proposed Public Offering of Common StockSoleno Therapeutics Announces Proposed Public Offering of Common Stock
globenewswire.com - May 2 at 4:01 PM
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Major Shareholder Vivo Opportunity, Llc Sells 750,000 SharesSoleno Therapeutics, Inc. (NASDAQ:SLNO) Major Shareholder Vivo Opportunity, Llc Sells 750,000 Shares
insidertrades.com - May 2 at 5:48 AM
Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi SyndromeSoleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome
globenewswire.com - April 30 at 8:00 AM
Soleno Therapeutics Gets Breakthrough Therapy Designation for Diazoxide CholineSoleno Therapeutics Gets Breakthrough Therapy Designation for Diazoxide Choline
marketwatch.com - April 29 at 4:41 PM
Soleno Therapeutics Shares Rise 37% After Breakthrough Designation for Diazoxide CholineSoleno Therapeutics Shares Rise 37% After Breakthrough Designation for Diazoxide Choline
marketwatch.com - April 29 at 4:41 PM
Soleno: Mid-2024 NDA Filing For PWS Treatment Is A Major Catalyst To WatchSoleno: Mid-2024 NDA Filing For PWS Treatment Is A Major Catalyst To Watch
seekingalpha.com - April 29 at 4:41 PM
Soleno Therapeutics (NASDAQ:SLNO) Shares Gap Up to $37.89Soleno Therapeutics (NASDAQ:SLNO) Shares Gap Up to $37.89
marketbeat.com - April 29 at 12:11 PM
Why Soleno Therapeutics Stock Is Skyrocketing TodayWhy Soleno Therapeutics Stock Is Skyrocketing Today
fool.com - April 29 at 11:11 AM
Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)
globenewswire.com - April 29 at 8:00 AM
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - April 19 at 4:05 PM
Soleno Therapeutics (NASDAQ:SLNO) Shares Up 3.4%Soleno Therapeutics (NASDAQ:SLNO) Shares Up 3.4%
marketbeat.com - April 15 at 2:49 PM
Carlyle Group Inc. Acquires 564,242 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO)Carlyle Group Inc. Acquires 564,242 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO)
marketbeat.com - April 14 at 8:45 PM
Soleno Therapeutics CEO sells over $780k in company stockSoleno Therapeutics CEO sells over $780k in company stock
investing.com - April 5 at 11:15 PM
Insider Selling: Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Sells 2,218 Shares of StockInsider Selling: Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Sells 2,218 Shares of Stock
insidertrades.com - April 4 at 6:49 AM
Insider Sell: CFO James Mackaness Sells 5,175 Shares of Soleno Therapeutics Inc (SLNO)Insider Sell: CFO James Mackaness Sells 5,175 Shares of Soleno Therapeutics Inc (SLNO)
finance.yahoo.com - April 4 at 3:16 AM
CEO Bhatnagar Anish Sells 18,980 Shares of Soleno Therapeutics Inc (SLNO)CEO Bhatnagar Anish Sells 18,980 Shares of Soleno Therapeutics Inc (SLNO)
finance.yahoo.com - April 4 at 3:16 AM
SLNO Apr 2024 40.000 putSLNO Apr 2024 40.000 put
finance.yahoo.com - March 16 at 10:33 PM
SLNO Apr 2024 35.000 putSLNO Apr 2024 35.000 put
finance.yahoo.com - March 16 at 7:31 AM
Construction of Solenos $22M pipe factory in Saratoga underwayConstruction of Soleno's $22M pipe factory in Saratoga underway
bizjournals.com - March 11 at 10:09 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

AdaptHealth logo

AdaptHealth

NASDAQ:AHCO
AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs. It also offers wheelchairs, hospital beds, oxygen concentrators, CPAP masks and related supplies, wound care supplies, diabetes management supplies, wheelchair cushion accessories, orthopedic bracing, breast pumps and supplies, walkers, commodes and canes, and nutritional and incontinence supplies. The company services beneficiaries of Medicare, Medicaid, and commercial insurance payors. The company is headquartered in Plymouth Meeting, Pennsylvania.
Omnicell logo

Omnicell

NASDAQ:OMCL
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Phreesia logo

Phreesia

NYSE:PHR
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, an on-site kiosks. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is based in Wilmington, Delaware.
Soleno Therapeutics logo

Soleno Therapeutics

NASDAQ:SLNO
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.